Avita Medical

RCEL

Market cap $113M

VALENCIA, Calif., Nov. 24, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (ASX: AVH, NASDAQ: RCEL), a leading therapeutic acute wound care company delivering transformative solutions, today announced that the Company will present at the Piper Sandler 37th Annual Healthcare Conference on Thursday, December 4, 2025, at 8:30 a.m.

The futures are trading higher after NVIDIA Inc. (NASDAQ: NVDA) blew out its fiscal third-quarter results and offered strong forward guidance, though perhaps not as robust as Wall Street had hoped.

AVITA Medical, Inc. ( RCEL ) Discusses Advanced Wound Care Solutions and Data-Driven Approaches in Clinical Healing November 12, 2025 5:00 PM EST Company Participants Ben Atkins - Vice President of Investor Relations & Corporate Communications Cary Vance - Independent Non-Executive Chairman & Interim CEO Presentation Ben Atkins Vice President of Investor Relations & Corporate Communications [Audio Gap] Cary Vance Independent Non-Executive Chairman & Interim CEO [Audio Gap] In each case, we believe our products are best from a clinical perspective, but also that they speed up the time to graft, the time to heal, which is extremely important for the patient and potential complications, but also important for the hospital that is trying to -- that is striving to make economic progress themselves. And so PermeaDerm is a biosynthetic dressing that protects the wound, that stabilizes the wound.

AVITA Medical, Inc. ( RCEL ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Ben Atkins - Vice President of Investor Relations & Corporate Communications Cary Vance - Independent Non-Executive Chairman & Interim CEO David OToole - Chief Financial Officer Conference Call Participants Ross Osborn - Cantor Fitzgerald & Co., Research Division Joshua Jennings - TD Cowen, Research Division Chris Kallos - MST Financial Services Pty Limited, Research Division Presentation Operator Good day, and thank you for standing by. Welcome to the AVITA Medical, Inc. Third Quarter 2025 Earnings Conference Call.

VALENCIA, Calif., Nov. 03, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company, today announced two podium presentations at the 2025 Southern Region Burn Conference (SRBC) that collectively underscore the clinical and economic value of the RECELL System and reinforce its role as a standard of care for acute wound treatment.

FLWS, BLIN and RCEL have been added to the Zacks Rank #5 (Strong Sell) List on October 31, 2025.

VALENCIA, Calif., Oct. 29, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company delivering transformative solutions, today announced that it will report its third quarter 2025 financial results after the close of the U.S. financial markets on Thursday, November 6, 2025.

NEW YORK--(BUSINESS WIRE)--Why: Rosen Law Firm, a global investor rights law firm, announces an investigation of potential securities claims on behalf of shareholders of AVITA Medical, Inc. (NASDAQ: RCEL) resulting from allegations that AVITA Medical may have issued materially misleading business information to the investing public. So What: If you purchased AVITA Medical securities you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee.

Australia's Medical Services Advisory Committee (MSAC) recognizes RECELL® as safe and effective, with benefits in healing, donor site sparing, and reduced hospital stays VALENCIA, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- AVITA Medical, Inc. (NASDAQ: RCEL, ASX: AVH) (“AVITA Medical,” or the “Company”), a leading therapeutic acute wound care company, today announced that Australia's Medical Services Advisory Committee (“MSAC”) has recommended amendments to the Medicare Benefits Schedule (“MBS”) to include the use of autologous skin cell suspension (“ASCS”) prepared with RECELL for the treatment of severe acute burn wounds in adults and children.

NEW YORK , Oct. 23, 2025 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of AVITA Medical, Inc. ("Avita" or the "Company") (NASDAQ: RCEL). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext.